This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Imprimis Pharmaceuticals' Pre-Commercial Ophthalmic Formulations To Be Presented At 2014 American-European Congress Of Ophthalmic Surgery (ACOS™)/Dulaney Winter Meeting

Stocks in this article: IMMY

SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that James Lewis, MD ( http://cataractphiladelphia.com), will present "Dropless Cataract Surgery" during the New Technologies Session of the American-European Congress of Ophthalmic Surgery (ACOS™). The society's Winter Meeting is being held February 23-26, 2014, in Aspen, Colorado. This will be the first time clinical data and clinical experience with Imprimis' dropless cataract surgery formulations and related administration techniques will be presented at a U.S. clinical meeting. ACOS ( http://acosurgery.org) represents and educates surgeons, innovators, and industry leaders who have made a significant contribution to the field of ophthalmology.

The Imprimis Pharmaceuticals proprietary ophthalmic therapies that Dr. Lewis will showcase during his presentation were prescribed by Dr. Lewis for more than 400 cataract surgery patients, and include a formulation combining triamcinolone acetonide, moxifloxacin hydrochloride and the antibiotic vancomycin. A second formulation is available with triamcinolone acetonide and moxifloxacin hydrochloride. Both of these proprietary formulations have been used by select physicians during thousands of cataract surgeries and many other eye surgeries where, as a result of the surgery, there is inflammation and a chance for post-operative infection. Dr. Lewis's presentation will include video in which he demonstrates a transzonular approach for the injection of the drugs intraoperatively. He will also examine the benefits of dropless cataract surgery for both doctors and patients. Dr. Lewis is not an employee or consultant of Imprimis.

This presentation by Dr. Lewis builds on Imprimis' strong momentum from participation at previous meetings, including the American Academy of Ophthalmology in New Orleans, La., the "Cataract Surgery: Telling It Like It is" meeting in Sarasota, Fla., and the Caribbean Eye Meeting in Cancun, Mexico. In addition to its presence at these meetings, the company has held several Ophthalmic Advisory Board meetings with national thought leaders.  Each of these events provides the opportunity to build relationships and gain valuable insight on the company's innovations and business model from the perspective of the ophthalmic surgeons who participate.

Imprimis previously announced plans to make available its proprietary ophthalmic compounded therapies during the first half of 2014, and is continuing its Go Dropless™ campaign ( http://GoDropless.com/). The campaign was created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.

ABOUT DROPLESS OPHTHALMIC SURGERY FORMULATIONSImprimis acquired the intellectual property for these patent-pending formulations in August of 2013. As the company stated at that time, the current treatment regimen for the prevention of post-cataract surgery complications is a costly pre-operative and post-operative patient-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack a supportive caregiver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues. Imprimis' unique drug formulations utilize a fourth generation quinolone therapy combined with anti-inflammatory agent, providing new choices for physicians to address the primary ocular complications of ophthalmic surgery - risk of infection and post-operative inflammation.

Imprimis believes that its proprietary formulations may have a broad application in ophthalmic surgery, including the multi-billion global cataract surgery drug market where the company believes there is an opportunity for technological advancement to meet patient interest to reduce or eliminate the need for post-surgery eye drops. The cataract surgery market continues exponential growth. Nearly 22 million cataract surgeries were performed globally in 2013, according to Market Scope. 1 This growth is not only due to the expanding aging population, but because the age at which patients demand cataract surgery has lowered, shown in a study by Mayo Clinic 2, portending the ophthalmology drug market to reach an estimated $21.6 billion by 2018 3.

ABOUT IMPRIMIS PHARMACEUTICALS San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Certain of Imprimis' patent-pending drug formulations are available today and are being prescribed by physicians.  For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBORThis press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make available its formulations during the expected timeframe or at all; physician interest in prescribing its formulations, Imprimis' ability to close the acquisition of Pharmacy Creations, LLC and realize the expected benefits of the transaction and enter , into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to commercialize its formulations and technologies, obtain intellectual property protection for its assets, its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary, risks related to research and development activities;, the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT:  Jen Carroll jcarroll@imprimispharma.com 858.704.4587

SOURCE Imprimis Pharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs